J Am Pharm Assoc (2003). 2023 May-Jun;63(3):863-872. doi: 10.1016/j.japh.2023.02.004. Epub 2023 Feb 8.
West Virginia (WV) has been at the forefront of the opioid crisis in the United States, with the highest rate of opioid overdose mortality involving prescription opioids in the country. To curb the crisis, the state government implemented a restrictive opioid prescribing law in March 2018, Senate Bill 273 (SB273), to decrease opioid prescribing. However, sweeping changes in opioid policy can have downstream effects on stakeholders such as pharmacists. This study is part of a sequential mixed methods investigation of the impact of SB273 in WV in which we interviewed various stakeholders-including pharmacists-about the impact of the law.
This paper aims to explore how pharmacy practice during the opioid crisis impacted the need for restrictive legislation and how SB273 impacted subsequent pharmacy practice in WV.
Semi-structured interviews were conducted with 10 pharmacists who were practicing in counties that had been designated as high-prescribing counties based upon county-level prescribing/dispensing data from state records. Analysis of the interviews was informed by the methodological orientation of content analysis to identify emerging themes.
Participants described confronting questionable opioid prescriptions, treatment costs, and insurance coverage driving opioids as a first-line choice for pain management, as well as the influence of corporate policies and the immense responsibility of being the "last line of defense" in the opioid crisis. A central impediment to the care of patients was the inability of the pharmacists to effectively communicate their concerns to prescribers, making improved prescriber-dispenser communication an essential next step in minimizing opioid care gaps.
This is one of few qualitative studies that have explored pharmacists' experiences, perceptions, and role in the opioid crisis leading up to and during the enactment of a restrictive opioid prescribing law. In light of the difficulties they faced, a restrictive opioid prescribing law was viewed positively by pharmacists.
西弗吉尼亚州(WV)一直处于美国阿片类药物危机的前沿,其涉及处方阿片类药物的阿片类药物过量死亡率为全美最高。为了遏制这一危机,州政府于 2018 年 3 月实施了一项限制阿片类药物处方的严格法规,即参议院法案 273 号(SB273),以减少阿片类药物的处方。然而,阿片类药物政策的全面改革可能会对药剂师等利益相关者产生下游影响。这项研究是对 SB273 在 WV 影响的一项顺序混合方法调查的一部分,我们对包括药剂师在内的各种利益相关者进行了访谈,了解该法律的影响。
本文旨在探讨阿片类药物危机期间的药房实践如何促使需要制定限制法规,以及 SB273 如何影响 WV 随后的药房实践。
对 10 名在根据州记录的县一级处方/配药数据被指定为高处方县的县执业的药剂师进行了半结构化访谈。对访谈的分析受到内容分析方法论取向的启发,以确定新兴主题。
参与者描述了面对有问题的阿片类药物处方、治疗费用和保险覆盖范围,将阿片类药物作为疼痛管理的一线选择,以及公司政策的影响和作为阿片类药物危机中“最后一道防线”的巨大责任。阻碍患者护理的一个主要障碍是药剂师无法有效地与处方者沟通他们的担忧,因此,改善处方者与配药者之间的沟通是缩小阿片类药物护理差距的重要下一步。
这是为数不多的探索药剂师在实施限制阿片类药物处方法规之前和期间在阿片类药物危机中所经历、看法和作用的定性研究之一。鉴于他们所面临的困难,限制阿片类药物处方的法规受到了药剂师的积极评价。